Cancer
Malignant Cervical Neoplasm
CI-CAN-00007992Explore in graph →
Top-level506 active trials4 approved drugs14 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00007992Explore in graph →
Clinical trials
1,994 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (181)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04150575 | A Clinical Study to Evaluate Efficacy and Safety of HLX10 Combined With Albumin-Bound Paclitaxel in Patients With Advanced Cervical Cancer Who Have Progressive Disease or Intolerable Toxicity After First-Line Standard Chemotherapy | unknown | Phase 2 | 21 | Shanghai Henlius BiotechINDUSTRY | 1 | May 9, 2022 | clinicaltrials |
| NCT05362669 | SMS Messaging for Invitation in the Cervical Cancer Screening Programme(CERCA-SMS) | unknown | N/A | 450 | Institut Català d'OncologiaOTHER | 1 |
| May 5, 2022 |
| clinicaltrials |
| NCT05359913 | Podcasting Cervical Cancer Prevention for AAW | unknown | N/A | 40 | University of HoustonOTHER | 0 | May 4, 2022 | clinicaltrials |
| NCT05342506 | Clinical Study on the Safety, Pharmacokinetics, and Efficacy of ScTIL (Genetically Modified Tumor Infiltrating Lymphocytes) in the Treatment of Gynecological Malignancies | unknown | Phase 2 | 30 | Peking Union Medical College HospitalOTHER | 0 | Apr 22, 2022 | clinicaltrials |
| NCT05314907 | Acceptability of Self-sampling for Cervical Cancer Screening | unknown | N/A | 1,614 | Institut d'Investigació Biomèdica de BellvitgeOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT05311566 | PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer | unknown | Phase 2 | 92 | Lei LiOTHER | 1 | Apr 13, 2022 | clinicaltrials |
| NCT05310305 | PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer | unknown | — | 20 | Lei LiOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT05310383 | Tislelizumab and Radiotherapy for Recurrent Cervical Cancer | unknown | Phase 2 | 58 | Lei LiOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT05321329 | Adjuvant CAPECITABINE in High Risk PSEUDOMYXOMA PERITONEI Patients(ACAPP) | unknown | Phase 2 | 28 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT05309122 | Cervical Cancer Screening Strategies | unknown | — | 10,000 | Lei LiOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT05310331 | Donafenib for Recurrent Cervical Cancer | unknown | Phase 2 | 20 | Lei LiOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT05259540 | Effect of Compound Kushen Injection Combined With Pabolizumab in the Treatment of Cervical Adenocarcinoma | unknown | Phase 2 | 42 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 1 | Mar 24, 2022 | clinicaltrials |
| NCT05290428 | DNA PAX1 and JAM3 Methylation for Cervical Cancer Screening | unknown | — | 459 | Peking Union Medical College HospitalOTHER | 1 | Mar 22, 2022 | clinicaltrials |
| NCT05290935 | Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy: Multi-Center Trial | unknown | Phase 2 | 122 | Lei LiOTHER | 1 | Mar 22, 2022 | clinicaltrials |
| NCT05087264 | Clinical Study of Indocyanine Green Displaying Pelvic Nerve in Radical Operation of Cervical Cancer | unknown | Early Phase 1 | 86 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Mar 18, 2022 | clinicaltrials |
| NCT03976973 | BromAc for Recurrent Peritoneal Mucinous Tumour or Pseudomyxoma Peritonei | unknown | Phase 2 | 62 | Mucpharm Pty LtdINDUSTRY | 0 | Mar 15, 2022 | clinicaltrials |
| NCT03221400 | PEN-866 in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 340 | Tarveda TherapeuticsINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT05236855 | Spectroscopy and Artificial Intelligence to Disrupt the Status Quo in Cervical Cancer Screening | unknown | — | 200 | IWK Health CentreOTHER | 0 | Feb 11, 2022 | clinicaltrials |
| NCT05180851 | Safety and Efficacy of Recombinant Oncolytic Adenovirus L-IFN Injection in Relapsed/Refractory Solid Tumors Clinical Study(YSCH-01) | unknown | Early Phase 1 | 28 | Shanghai Fengxian District Central HospitalOTHER | 1 | Feb 1, 2022 | clinicaltrials |
| NCT05210348 | Clinical Evaluation of Detection of High Risk HPV in Urine(Urine-hrHPV) | unknown | — | 1,000 | Peking University People's HospitalOTHER | 1 | Jan 27, 2022 | clinicaltrials |
| NCT05185713 | The Mechanism of Vaginal Flora and Its Metabolites in the Pathogenesis of Cervical Cancer | unknown | — | 300 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jan 25, 2022 | clinicaltrials |
| NCT04371887 | Comparing Strategies for Implementing Primary HPV Screening | unknown | N/A | 45,000 | Chun ChaoOTHER | 1 | Dec 30, 2021 | clinicaltrials |
| NCT05167149 | Carbon Nanoparticles and Indocyanine Green for Sentinel Lymph Node Biopsy in Early Stage Cervical Cancer | unknown | N/A | 144 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Dec 22, 2021 | clinicaltrials |
| NCT03668639 | Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin | unknown | Phase 2 / Phase 3 | 80 | Christina RuhlmannOTHER | 1 | Dec 14, 2021 | clinicaltrials |
| NCT05068921 | A Clinical Trial to Evaluate Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignancy | unknown | Phase 1 | 40 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Dec 13, 2021 | clinicaltrials |
| NCT05059015 | Human Papilloma Virus (HPV) Self-collection and Women Adherence | unknown | N/A | 80 | Instituto Nacional de Cancerologia, ColumbiaOTHER_GOV | 1 | Dec 10, 2021 | clinicaltrials |
| NCT05151549 | A Study of Carilizumab Combined With Concurrent Chemoradiotherapy | unknown | Phase 2 | 46 | Hunan Cancer HospitalOTHER | 0 | Dec 9, 2021 | clinicaltrials |
| NCT05137171 | AK105 Combined With Anlotinib in Patients With Cervical Cancer | unknown | Phase 2 | 36 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | Nov 30, 2021 | clinicaltrials |
| NCT04443296 | Study of Tumor Infiltrating Lymphocytes Following CCRT in the Treatment of Patients With Cervical Carcinoma(TIL-Cx) | unknown | Phase 1 | 10 | Sun Yat-sen UniversityOTHER | 1 | Nov 16, 2021 | clinicaltrials |
| NCT04934982 | Laparoscopic or Abdominal Radical Hysterectomy for Cervical Cancer(Stage IA1 With LVSI, IA2)(LAUNCH 1) | unknown | N/A | 690 | Hua JiangOTHER | 1 | Nov 10, 2021 | clinicaltrials |
| NCT04939831 | Laparoscopic or Abdominal Radical Hysterectomy for Cervical Cancer(Stage IB3,IIA2)(LAUNCH 3) | unknown | N/A | 1,104 | Obstetrics & Gynecology Hospital of Fudan UniversityOTHER | 1 | Nov 10, 2021 | clinicaltrials |
| NCT04214964 | Clinical Characters of the Diagnosis and Treatment of Gynecological Malignant Tumors in China : A Real World Study | unknown | — | 10,000 | Tongji HospitalOTHER | 1 | Oct 7, 2021 | clinicaltrials |
| NCT00108745 | Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer | unknown | Phase 3 | 1,157 | GOG FoundationNETWORK | 1 | Sep 30, 2021 | clinicaltrials |
| NCT02388698 | FDG-PET and Circulating HPV in Patients With Cervical Cancer | unknown | N/A | 84 | Sunnybrook Health Sciences CentreOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT04731038 | Combination Therapy for First Line Treatment of Advanced Cervical Cancer | unknown | Phase 1 | 20 | Ruijin HospitalOTHER | 1 | Sep 17, 2021 | clinicaltrials |
| NCT00980759 | Prophylactic Irradiation of the Para-Aortic Lymph Nodes in Locally Advanced Uterine Cervical Cancer | unknown | N/A | 312 | National Cancer Center, KoreaOTHER_GOV | 1 | Sep 8, 2021 | clinicaltrials |
| NCT04238988 | Carboplatin-Paclitaxel-Pembrolizumab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer(MITO CERV 3) | unknown | Phase 2 | 45 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Aug 27, 2021 | clinicaltrials |
| NCT05013268 | Tislelizumab Plus TP as Neoadjuvant Therapy for Local Advanced Cervical Carcinoma(TiTanec) | unknown | Phase 1 | 15 | Ruijin HospitalOTHER | 1 | Aug 24, 2021 | clinicaltrials |
| NCT04974827 | A Study of Camrelizumab Combined With Concurrent Chemoradiation in Patients With Cervical Cancer | unknown | Phase 2 | 46 | Hunan Cancer HospitalOTHER | 1 | Aug 10, 2021 | clinicaltrials |
| NCT04974424 | Early Warning Model of Susceptibility and High-risk Population of Cervical Cancer Related to HPV | unknown | — | 20,000 | Huazhong University of Science and TechnologyOTHER | 1 | Jul 23, 2021 | clinicaltrials |
| NCT04973904 | Toripalimab Combined With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Cervical Cancer | unknown | Phase 2 | 35 | Peking Union Medical College HospitalOTHER | 1 | Jul 22, 2021 | clinicaltrials |
| NCT04905030 | Education, Immigration and HPV Vaccination: an Informational Randomized Trial | unknown | N/A | 2,500 | Karolinska InstitutetOTHER | 1 | Jun 11, 2021 | clinicaltrials |
| NCT04918628 | Adjuvant Chemotherapy and Anti-PD-1 Antibody in Patients With Stage IIIC2-IVB Cervical Cancer(CRTCP) | unknown | Phase 2 | 50 | Taizhou HospitalOTHER | 1 | Jun 9, 2021 | clinicaltrials |
| NCT04556669 | Anti-PD-L1 Armored Anti-CD22 CAR-T/CAR-TILs Targeting Patients With Solid Tumors | unknown | Phase 1 | 30 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | May 27, 2021 | clinicaltrials |
| NCT04395612 | Niraparib Combined With Brivanib or Toripalimab in Patients With Cervical Cancer(CQGOG0101) | unknown | Phase 2 | 38 | Chongqing University Cancer HospitalOTHER | 1 | May 21, 2021 | clinicaltrials |
| NCT03676959 | A Clinical Study of PD-L1 Antibody ZKAB001（Drug Code） in Recurrent or Metastatic Cervical Cancer | unknown | Phase 1 | 101 | Lee's Pharmaceutical LimitedINDUSTRY | 1 | May 13, 2021 | clinicaltrials |
| NCT04884906 | Camrelizumab Combined With Radiotherapy and Chemotherapy for the Treatment of Recurrent or Metastatic Cervical Cancer | unknown | Phase 2 | 40 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 13, 2021 | clinicaltrials |
| NCT03852823 | Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours | unknown | Phase 1 | 192 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Apr 30, 2021 | clinicaltrials |
| NCT04868097 | Predicting Adjuvant Post-operative Radiation Therapy in Patients With Cervical Cancer Stage IB2 | unknown | N/A | 52 | Kaplan Medical CenterOTHER | 1 | Apr 30, 2021 | clinicaltrials |
| NCT04819685 | Application of KANG FU PEN in Radical Concurrent Radiotherapy and Chemotherapy for Cervical Cancer to Prevent and Treat Radiation-induced Rectal Injury | unknown | Phase 4 | 520 | Peking Union Medical College HospitalOTHER | 1 | Mar 29, 2021 | clinicaltrials |
Data updated 23 days agoSource updated May 9, 2022source: clinicaltrials